Assessing the Response of Biomarkers to Anti-Inflammatory Medications in PIMS-TS by Longitudinal Multilevel Modeling: Real-World Data from a UK Tertiary Center.

IF 1.1 4区 医学 Q4 ALLERGY
Pediatric Allergy Immunology and Pulmonology Pub Date : 2023-09-01 Epub Date: 2023-07-11 DOI:10.1089/ped.2023.0024
Joseph J Tonge, Olivia Stevens, Jeremy Dawson, Daniel Hawley, Caroline Kerrison, Nils Krone, Sarah L Maltby, Anne-Marie McMahon, Fiona Shackley, Rupa Talekar, Carmen Gonzalez-Martinez, Neil Lawrence
{"title":"Assessing the Response of Biomarkers to Anti-Inflammatory Medications in PIMS-TS by Longitudinal Multilevel Modeling: Real-World Data from a UK Tertiary Center.","authors":"Joseph J Tonge,&nbsp;Olivia Stevens,&nbsp;Jeremy Dawson,&nbsp;Daniel Hawley,&nbsp;Caroline Kerrison,&nbsp;Nils Krone,&nbsp;Sarah L Maltby,&nbsp;Anne-Marie McMahon,&nbsp;Fiona Shackley,&nbsp;Rupa Talekar,&nbsp;Carmen Gonzalez-Martinez,&nbsp;Neil Lawrence","doi":"10.1089/ped.2023.0024","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Pediatric inflammatory multisystem syndrome temporarily associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PIMS-TS) is an acute complication of previous SARS-CoV-2 exposure. The relationship between inflammatory markers and anti-inflammatory medication in PIMS-TS is unknown. We retrospectively investigated the relationship between demographics, biomarkers, treatment, and length of stay (LOS) in this novel disease. <b><i>Methods:</i></b> We reviewed the case notes and blood tests of all patients who met the Royal College of Paediatrics and Child Health diagnostic criteria for PIMS-TS at a large tertiary center in the United Kingdom. Biomarker trajectories were modeled using log linear mixed effects, and factors affecting LOS in hospital were evaluated using multiple regression. <b><i>Results:</i></b> Between March 2020 and May 2022, a total of 56 patients attended Sheffield Children's Hospital with PIMS-TS, 70% male. Mean age was 7.4 ± 3.7 years and mean LOS 8.7 ± 4.5 days with 50% requiring intensive care and 20% requiring inotropes. Older males had shorter LOS than younger males (<i>P</i> = 0.04), not seen in females. Treatment included intravenous glucocorticoids in 93%, intravenous immunoglobulins (IVIG) in 77%, Anakinra in 11%, and infliximab in 1.8%. Biomarkers correlated poorly with trajectories that peaked at different times. C-reactive protein peaked first after median 1.3 days postadmission; while LFT's and neutrophils peaked after 3 days. Age had a large effect on some biomarkers, with older children having larger troponin and ferritin, and lower lymphocytes and platelets. Cumulative dose of glucocorticoids and IVIG had a statistically significant effect on some biomarkers, but effect size was small. <b><i>Conclusions:</i></b> The heterogenous nature of PIMS-TS highlights the importance of a multidisciplinary approach. Worse inflammatory markers in older children within our cohort may be an indication of a different disease process occurring at different ages. Future work to investigate the association between age and troponin and ferritin in hyperinflammatory states is warranted.</p>","PeriodicalId":54389,"journal":{"name":"Pediatric Allergy Immunology and Pulmonology","volume":"36 3","pages":"94-103"},"PeriodicalIF":1.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Allergy Immunology and Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ped.2023.0024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pediatric inflammatory multisystem syndrome temporarily associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PIMS-TS) is an acute complication of previous SARS-CoV-2 exposure. The relationship between inflammatory markers and anti-inflammatory medication in PIMS-TS is unknown. We retrospectively investigated the relationship between demographics, biomarkers, treatment, and length of stay (LOS) in this novel disease. Methods: We reviewed the case notes and blood tests of all patients who met the Royal College of Paediatrics and Child Health diagnostic criteria for PIMS-TS at a large tertiary center in the United Kingdom. Biomarker trajectories were modeled using log linear mixed effects, and factors affecting LOS in hospital were evaluated using multiple regression. Results: Between March 2020 and May 2022, a total of 56 patients attended Sheffield Children's Hospital with PIMS-TS, 70% male. Mean age was 7.4 ± 3.7 years and mean LOS 8.7 ± 4.5 days with 50% requiring intensive care and 20% requiring inotropes. Older males had shorter LOS than younger males (P = 0.04), not seen in females. Treatment included intravenous glucocorticoids in 93%, intravenous immunoglobulins (IVIG) in 77%, Anakinra in 11%, and infliximab in 1.8%. Biomarkers correlated poorly with trajectories that peaked at different times. C-reactive protein peaked first after median 1.3 days postadmission; while LFT's and neutrophils peaked after 3 days. Age had a large effect on some biomarkers, with older children having larger troponin and ferritin, and lower lymphocytes and platelets. Cumulative dose of glucocorticoids and IVIG had a statistically significant effect on some biomarkers, but effect size was small. Conclusions: The heterogenous nature of PIMS-TS highlights the importance of a multidisciplinary approach. Worse inflammatory markers in older children within our cohort may be an indication of a different disease process occurring at different ages. Future work to investigate the association between age and troponin and ferritin in hyperinflammatory states is warranted.

通过纵向多水平建模评估PIMS-TS中生物标志物对抗炎药物的反应:来自英国第三中心的真实世界数据。
背景:与严重急性呼吸系统综合征冠状病毒2型感染(PIMS-TS)暂时相关的儿童炎症性多系统综合征是既往接触严重急性呼吸综合征冠状病毒的急性并发症。PIMS-TS中炎症标志物与抗炎药物之间的关系尚不清楚。我们回顾性研究了这种新型疾病的人口统计学、生物标志物、治疗和住院时间(LOS)之间的关系。方法:我们回顾了在英国一家大型三级中心符合皇家儿科和儿童健康学院PIMS-TS诊断标准的所有患者的病例记录和血液测试。使用对数线性混合效应对生物标志物轨迹进行建模,并使用多元回归评估影响医院服务水平的因素。结果:在2020年3月至2022年5月期间,共有56名PIMS-TS患者在谢菲尔德儿童医院就诊,其中70%为男性。平均年龄7.4岁 ± 3.7年,平均服务水平8.7 ± 4.5天,其中50%需要重症监护,20%需要止痛药。老年男性的LOS较年轻男性短(P = 0.04),女性未见。治疗包括93%的静脉注射糖皮质激素,77%的静脉注射免疫球蛋白(IVIG),11%的Anakinra和1.8%的英夫利昔单抗。生物标志物与不同时间达到峰值的轨迹相关性较差。C反应蛋白在入院后中位数1.3天后首先达到峰值;LFT和中性粒细胞在3天后达到峰值。年龄对一些生物标志物有很大影响,年龄较大的儿童肌钙蛋白和铁蛋白较高,淋巴细胞和血小板较低。糖皮质激素和IVIG的累积剂量对一些生物标志物有统计学意义的影响,但影响范围很小。结论:PIMS-TS的异质性突出了多学科方法的重要性。在我们的队列中,年龄较大的儿童中更糟糕的炎症标志物可能表明不同年龄段发生了不同的疾病过程。未来有必要研究高炎症状态下年龄与肌钙蛋白和铁蛋白之间的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
23
审稿时长
>12 weeks
期刊介绍: Pediatric Allergy, Immunology, and Pulmonology is a peer-reviewed journal designed to promote understanding and advance the treatment of respiratory, allergic, and immunologic diseases in children. The Journal delivers original translational, clinical, and epidemiologic research on the most common chronic illnesses of children—asthma and allergies—as well as many less common and rare diseases. It emphasizes the developmental implications of the morphological, physiological, pharmacological, and sociological components of these problems, as well as the impact of disease processes on families. Pediatric Allergy, Immunology, and Pulmonology coverage includes: -Functional and genetic immune deficiencies- Interstitial lung diseases- Both common and rare respiratory, allergic, and immunologic diseases- Patient care- Patient education research- Public health policy- International health studies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信